← Leaderboards
Roger L Papke
University Of Florida
$7,586,439
Attributed
$7,586,439
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $508.5K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,586,439 · 1
By mechanism
R01$7,586,439 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Nicotinic Receptors”
- Marina R. Picciotto · Yale University$25,752,267
- Henry A. Lester · California Institute Of Technology$20,487,222
- Nicholas David Cosford · Sanford Burnham Prebys Medical Discovery Institute$17,620,368
- Paul J Kenny · Icahn School Of Medicine At Mount Sinai$17,249,281
- Lindsay H Burns · Cassava Sciences, Inc$16,572,741
- Linda P Dwoskin · University Of Kentucky$15,438,153
Research focus
Nicotinic ReceptorsS DiseaseAgonistAlpha-Bungarotoxin ReceptorDesensitizationAlzheimer&AposMutantPropertySiteSchizophreniaMolecular ConformationLigandsTherapeutic EffectTherapeutic TargetReceptorDesignPharmaceutical PreparationsBaseNicotineStructureBinding SitesMolecularAminesNeurons
Grant awards (21)
Targeting of Alpha7 nAChR for therapeutic effects$456,503
R01 · FY2023 · GM · contact PI
Targeting of Alpha7 nAChR for therapeutic effects$456,846
R01 · FY2022 · GM · contact PI
Targeting of Alpha7 nAChR for therapeutic effects$463,932
R01 · FY2021 · GM · contact PI
Targeting of Alpha7 nAChR for therapeutic effects$508,549
R01 · FY2020 · GM · contact PI
Targeting of alpha7 nAChR for therapeutic effects$409,249
R01 · FY2019 · GM · contact PI
Targeting of alpha7 nAChR for therapeutic effects$420,499
R01 · FY2018 · GM · contact PI
Targeting of alpha7 nAChR for therapeutic effects$424,601
R01 · FY2017 · GM · contact PI
Targeting of alpha7 nAChR for therapeutic effects$447,555
R01 · FY2016 · GM · contact PI
Targeting of alpha7 nAChR for therapeutic effects$422,170
R01 · FY2014 · GM · contact PI
Targeting of alpha7 nAChR for therapeutic effects$407,396
R01 · FY2013 · GM · contact PI
Targeting of alpha7 nAChR for therapeutic effects$433,328
R01 · FY2012 · GM · contact PI
Targeting of alpha7 nAChR for therapeutic effects$442,527
R01 · FY2011 · GM · contact PI
Targeting alpha7 nAChR for Therapeutic Effects$73,184
R01 · FY2010 · GM · contact PI
Targeting alpha7 nAChR for Therapeutic Effects$301,409
R01 · FY2008 · GM · contact PI
Targeting alpha7 nAChR for Therapeutic Effects$310,411
R01 · FY2007 · GM · contact PI
Targeting alpha7 nAChR for Therapeutic Effects$319,682
R01 · FY2006 · GM · contact PI
Targeting alpha7 nAChR for Therapeutic Effects$324,740
R01 · FY2005 · GM
TARGETING ALPHA7 NACHR FOR THERAPEUTICS EFFECTS$251,622
R01 · FY2003 · GM
TARGETING ALPHA7 NACHR FOR THERAPEUTICS EFFECTS$244,377
R01 · FY2002 · GM
TARGETING ALPHA7 NACHR FOR THERAPEUTICS EFFECTS$237,344
R01 · FY2001 · GM
TARGETING ALPHA7 NACHR FOR THERAPEUTICS EFFECTS$230,515
R01 · FY2000 · GM